Evidence map›Paper›PMID 41684603›Full record

ArticleFrontiers in oncology2026

Safety and feasibility assessment of implantable chest wall venous access port for patients with acute leukemia.

Peng Ke, Min Liao, Fan He, Ying Xu, Guoqiang Li, Lina Hu, Chun Feng, Ruiting Zhang, Yanhong Ding, Jihao Zhou and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Peng Ke *Department of Hematology, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China.
Min Liao *Department of Hematology, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China.
Fan HeDepartment of Invasive Technology, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China.
Ying XuDepartment of Hematology, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China.
Guoqiang LiDepartment of Hematology, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China.
Lina HuDepartment of Hematology, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China.
Chun FengDepartment of Hematology, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China.
Ruiting ZhangDepartment of Hematology, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China.
Yanhong DingDepartment of Hematology, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China.
Jihao ZhouDepartment of Hematology, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China.
Jialing LuShanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yixuan CaoDepartment of Hematology, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Totally implantable venous access ports (TIVAPs) are widely used in chemotherapy for solid malignant tumors. However, there are currently few data on the application of TIVAPs in patients with acute leukemia. The purpose of this study was to evaluate the safety and feasibility of TIVAPs in patients with acute leukemia. Methods: A single-institute retrospective review was performed on 94 adult patients with acute leukemia who underwent TIVAPs at Shenzhen People's Hospital between January 2020 and April 2025. Baseline characteristics and TIVAP-related complications were evaluated. Results: Among of 94 patients, all TIVAPs were successfully implanted. No intraoperative complications occurred. Early postoperative complications (less than 30 days postoperatively) occurred in five (5.3%) patients, including local subcutaneous hematoma (n=3, 3.2%) and infection (n=2, 2.1%). Only two patients (n=2, 2.1%) developed late postoperative complications (more than 30 days postoperatively), including one catheter-related deep vein thrombosis and one catheter dysfunction. Three of 94 patients (3.2%) required premature TIVAPs removal due to localized bleeding complications or catheter-related bloodstream infection. As of June 1, 2025, the median dwelling time of TIVAPs was 26.6 months (range: 0.1-76.4 months). The 2-year of cumulative hematoma-free catheter survival rates was 96.8% ± 1.81%. The 2-year of cumulative adverse event-free catheter survival rates was 93.5% ± 2.55%. Conclusions: Our study shows that TIVAP can provide a safe and effective system for long-term intravenous treatment of patients with acute leukemia. Therefore, TIVAP is another potentially effective and safe option for patients with acute leukemia.

Indexed as

acute leukemiafeasibilitysafetyTIVAP-related complicationstotally implantable venous access ports

Identifiers

PMID41684603
PMCPMC12890632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.